CAS 163451-81-8
:Teriflunomida
Descripción:
Teriflunomida es un fármaco inmunomodulador utilizado principalmente en el tratamiento de la esclerosis múltiple. Es un inhibidor de la síntesis de pirimidina que actúa inhibiendo selectivamente la enzima dihidroorotato deshidrogenasa, que es crucial para la proliferación de linfocitos activados. Este mecanismo reduce el número de linfocitos circulantes, modulando así la respuesta inmune. Teriflunomida se caracteriza por su vida media relativamente larga, lo que permite una dosificación oral una vez al día. El compuesto se presenta típicamente como una mezcla racémica, siendo su forma activa el isómero levorotatorio. Tiene una solubilidad moderada en agua y es lipofílico, lo que ayuda en su absorción y distribución en el cuerpo. Los efectos secundarios comunes pueden incluir elevaciones de enzimas hepáticas, trastornos gastrointestinales y posibles efectos teratogénicos, lo que requiere un monitoreo cuidadoso durante el tratamiento. Debido a sus propiedades inmunosupresoras, es esencial que los pacientes sean examinados en busca de infecciones y otras contraindicaciones antes de iniciar la terapia. En general, Teriflunomida representa un avance significativo en el manejo de condiciones autoinmunitarias, particularmente la esclerosis múltiple.
Fórmula:C12H9F3N2O2
InChI:InChI=1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-
Clave InChI:InChIKey=UTNUDOFZCWSZMS-YFHOEESVSA-N
SMILES:C(F)(F)(F)C1=CC=C(NC(/C(=C(/C)\O)/C#N)=O)C=C1
Sinónimos:- (2Z)-2-(hydroxy{[4-(trifluoromethyl)phenyl]amino}methylidene)-3-oxobutanenitrile
- (2Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide
- (Z)-2-Cyano-alpha'alpha'alpha-trifluoro-3-hydroxy-p-crotonotoluidide
- 2-Butenamide, 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-
- 2-Butenamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-, (2Z)-
- 2-Butenamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-, (Z)-
- 2-Cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide
- A 1726
- A 77-1726
- A 771726
- A771726
- Active metabolite of leflunomide
- Aubagio
- Femorix
- Flucyamide
- Hmr 1726
- Malononitrilamide
- N-(4-Trifluoromethylphenyl)-2-cyano-2-hydroxycrotonamide
- Su 20
- Teriflunomide
- Teriflunomide [INN]
- Ver más sinónimos
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Encontrado 17 productos.
Leflunomide Related Compound B (Z)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)but-2-enamide
CAS:Nitrile function compounds, not elsewhere specified or includedFórmula:C12H9F3N2O2Forma y color:White Off-White PowderPeso molecular:270.06161Teriflunomide
CAS:Nitrile function compounds, nesoiFórmula:C12H9F3N2O2Forma y color:White Crystalline PowderPeso molecular:270.061612-Butenamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-, (2Z)-
CAS:Fórmula:C12H9F3N2O2Pureza:99%Forma y color:SolidPeso molecular:270.2073Leflunomide EP Impurity B (Leflunomide USP Related Compound B, Teriflunomide)
CAS:Fórmula:C12H9F3N2O2Forma y color:White To Off-White SolidPeso molecular:270.21Leflunomide EP Impurity B-d4 (Leflunomide USP Related Compound B-d4, Teriflunomide-d4)
CAS:Fórmula:C12H5D4F3N2O2Forma y color:White To Off-White SolidPeso molecular:274.24Teriflunomide
CAS:Fórmula:C12H9F3N2O2Pureza:>98.0%(GC)Forma y color:White to Almost white powder to crystalPeso molecular:270.21(2Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide (Teriflunomide)
CAS:Producto controladoFórmula:C12H9F3N2O2Forma y color:NeatPeso molecular:270.21Teriflunomide
CAS:<p>Teriflunomide (A 77-1726) is the principal active metabolite of leflunomide, an approved therapy for rheumatoid arthritis and multiple sclerosis.</p>Fórmula:C12H9F3N2O2Pureza:99.54% - 99.95%Forma y color:SolidPeso molecular:270.21A 77-1726
CAS:<p>Impurity Leflunomide EP Impurity B<br>Applications A77 1726 (Leflunomide EP Impurity B) is the active metabolite of Leflunomide, a potent disease-modifying antirheumatic drug used in the treatment of rheumatoid arthritis. LEF-M interferes with dendritic cell function. The second Phase III study evaluating the efficacy of Genzyme’s teriflunomide therapy against relapsing forms of multiple sclerosis found the once-daily oral drug to be no less effective than injectable interferon beta 1a (Rebif®).<br>References Kirsch, B.M., et al.: Arthritis Research and Therapy, 7, 3, R694, (2005)<br></p>Fórmula:C12H9F3N2O2Forma y color:White To Off-WhitePeso molecular:270.21Teriflunomide
CAS:Producto controlado<p>Inhibitor of dihydroorotate dehydrogenase; anti-inflammatory; immunomodulatory</p>Fórmula:C12H9F3N2O2Pureza:Min. 98 Area-%Forma y color:White PowderPeso molecular:270.21 g/molTeriflunomide
CAS:Producto controlado<p>Teriflunomide is a drug that has been clinically proven for the treatment of multiple sclerosis. It is a prodrug that is converted to its active form, teriflunomide-phosphate, in vivo. Teriflunomide inhibits the activity of matrix metalloproteinases by blocking Ca2+ channels and inhibiting Ca2+ influx into the cytosol. This blocks the degradation of extracellular matrix proteins and reduces inflammation, which may lead to long-term efficacy in autoimmune diseases such as multiple sclerosis. Teriflunomide also decreases T-cell proliferation by inhibiting integrin receptors on T cells and monoclonal antibody production.</p>Fórmula:C12H9F3N2O2Pureza:Min. 98 Area-%Peso molecular:270.21 g/mol
![2-Butenamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-, (2Z)-](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA001U44.jpg&w=3840&q=75)
![(2Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide (Teriflunomide)](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2F86%2Fthumb%2FMM0859.02.jpg&w=3840&q=75)
